Lixte Biotech Appoints New CMO, Director
Ticker: LIXT · Form: 8-K · Filed: Jun 5, 2024 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 8-K |
| Filed Date | Jun 5, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-appointment, material-agreement
TL;DR
Lixte Biotech brings in new CMO and a board member, signs a big deal.
AI Summary
Lixte Biotechnology Holdings, Inc. announced on May 31, 2024, the appointment of Dr. John B. McCarthy as Chief Medical Officer and the election of Ms. Susan A. Froehlich to its Board of Directors. The company also entered into a material definitive agreement, the details of which are not fully disclosed in this filing.
Why It Matters
The appointment of a new Chief Medical Officer and a new Board member can signal strategic shifts or new directions for the company's research and development or corporate governance.
Risk Assessment
Risk Level: medium — Changes in key leadership and the entry into material agreements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- Dr. John B. McCarthy (person) — Appointed Chief Medical Officer
- Ms. Susan A. Froehlich (person) — Elected to Board of Directors
- May 31, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. John B. McCarthy has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Susan A. Froehlich has been elected to the Board of Directors.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is May 31, 2024.
What type of agreement did Lixte Biotechnology Holdings, Inc. enter into?
Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement.
What is the Standard Industrial Classification for Lixte Biotechnology Holdings, Inc.?
The Standard Industrial Classification for Lixte Biotechnology Holdings, Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 1,061 words · 4 min read · ~4 pages · Grade level 9.9 · Accepted 2024-06-05 15:55:25
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 66KB
- ex99-1.htm (EX-99.1) — 17KB
- 0001493152-24-022709.txt ( ) — 363KB
- lixt-20240531.xsd (EX-101.SCH) — 4KB
- lixt-20240531_def.xml (EX-101.DEF) — 26KB
- lixt-20240531_lab.xml (EX-101.LAB) — 36KB
- lixt-20240531_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 5, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan Chief Executive Officer 3 INDEX TO EXHIBITS Exhibit No. Description 10.1 Consulting Agreement dated as of May 31, 2024 between the Company and Dr. Jan Schellens. 99.1 Press Release regarding the appointment of Dr. Jan Schellens as Chief Medical Officer. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) 4